Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
NCT ID NCT04974944
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 2 trial compares a new combination of camrelizumab (an immunotherapy) plus apatinib (a targeted therapy) against the standard chemotherapy plus bevacizumab as a first treatment for women with stage IVB, recurrent, or persistent cervical cancer. The study aims to see if the new combo can delay cancer progression better than the current approach. About 35 participants will be randomly assigned to one of the two treatment groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab plus apatinib
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced cervical cancer that may be more effective than current standard therapy.
- What could go wrong
- This is a small phase 2 trial, so results may not confirm benefit. The combination also carries risks of immune-related side effects and high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Blood test may spot returning cervical cancer before symptoms appear
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- Immunotherapy combo shows promise for advanced cervical cancer
- New combo therapy shows promise for Tough-to-Treat cervical cancer
- New combo therapy offers hope for advanced cervical cancer patients